Polyoxometalates: metallodrug agents for combating amyloid aggregation
Authors:
Open Access
- 13 June 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in National Science Review
- Vol. 11 (7) , nwae226
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative disease that affects ∼50 million people globally. The accumulation of amyloid-β (Aβ) plaques, a predominant pathological feature of AD, plays a crucial role in AD pathogenesis. In this respect, Aβ has been regarded as a highly promising therapeutic target for AD treatment. Polyoxometalates (POMs) are a novel class of metallodrugs being developed as modulators of Aβ aggregation, owing to their negative charge, polarity, and three-dimensional structure. Unlike traditional discrete inorganic complexes, POMs contain tens to hundreds of metal atoms, showcasing remarkable tunability and diversity in nuclearities, sizes, and shapes. The easily adjustable and structurally variable nature of POMs allows for their favorable interactions with Aβ. This mini-review presents a balanced overview of recent progress in using POMs to mitigate amyloidosis. Clear correlations between anti-amyloid activities and structural features of POMs are also elaborated in detail. Finally, we discuss the current challenges and future prospects of POMs in combating AD.Keywords
Funding Information
- National Key Research and Development Program of China (2019YFA0709202, 2021YFF1200700, 2022YFA1205804)
- National Natural Science Foundation of China (21820102009, 22237006)
This publication has 80 references indexed in Scilit:
- Polyoxometalate based open-frameworks (POM-OFs)Chemical Society Reviews, 2014
- Recent advances in porous polyoxometalate-based metal–organic framework materialsChemical Society Reviews, 2014
- Transition-metal-substituted polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer’s diseaseNature Communications, 2014
- Mo polyoxometalate nanoclusters capable of inhibiting the aggregation of Aβ-peptide associated with Alzheimer's diseaseNanoscale, 2014
- Self‐Assembled Peptide–Polyoxometalate Hybrid Nanospheres: Two in One Enhances Targeted Inhibition of Amyloid β‐Peptide Aggregation Associated with Alzheimer's DiseaseSmall, 2013
- Engineering polyoxometalates with emergent propertiesChemical Society Reviews, 2012
- Diphosphates and diphosphonates in polyoxometalate chemistryChemical Society Reviews, 2012
- Metallostasis and amyloid β-degrading enzymesMetallomics, 2012
- Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting EnzymeJournal of Biological Chemistry, 2001
- How Strong Is a Covalent Bond?Science, 1999